PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022

News provided by

Apr 10, 2013, 11:46 ET

NEW YORK, April 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01158419/PharmaPoint-Osteoporosis---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Summary

GlobalData has released its new Country report, "PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

As in India, recession of the market for branded products will be caused by floods of generic products into the market. Like India, China will likely start issuing compulsory licenses for Chinese generics companies to violate IP rights and produce drugs prior to patent expiries. Therefore, GlobalData expects the Chinese market to be dominated by generic products, and to lose significant value in the branded side of the drug market. GlobalData did not project the pipeline products launching in the major markets because sales will likely be retarded by generic products.

Scope

- Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Osteoporosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.1.3 Risk Factors 16
3.1.4 Quality of Life 16
3.2 Symptoms 17
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referral 18
4.1.2 Treatment Guidelines 19
4.1.3 Disease Management 20
4.2 China 23
4.2.1 Diagnosis 23
4.2.2 Clinical Practice 24
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 25
5.3 Product Profiles – Major Brands 29
5.3.1 Actonel (risedronate sodium) 29
5.3.2 Evista (raloxifene hydrochloride) 32
5.3.3 Reclast (zolendronic acid) 35
5.3.4 Forteo (teriparatide) 38
5.3.5 Prolia (denosumab) 42
5.3.6 Protelos (strontium ranelate) 45
5.3.7 Miacalcin and Fortical (calcitonin-salmon) 48
5.3.8 Viviant/Conbriza (bazedoxifene) 51
5.3.9 Recalbon/Bonoteo (minodronic acid hydrate) 54
5.3.10 Alendronate sodium 56
5.3.11 Ibandronate 58
6 Opportunity and Unmet Need 59
6.1 Overview 59
6.2 Unmet Needs 59
6.2.1 Disease Awareness and Early Diagnosis 59
6.2.2 Patient Compliance 60
6.2.3 Efficacy 61
6.2.4 Safety 61
6.2.5 Treatment Cost 62
6.2.6 Earlier Intervention 62
6.3 Unmet Needs Gap Analysis 63
6.4 Opportunity 1: Dual-Action Therapies 64
6.5 Opportunity 2: Osteoporosis Prevention Therapies 65
6.6 Opportunity 3: Dosing and Administration 65
7 Market Outlook 66
7.1 China 66
7.1.1 Forecast 66
7.1.2 Key Events 68
7.1.3 Drivers and Barriers 69
8 Appendix 70
8.1 Bibliography 70
8.2 Abbreviations 76
8.3 Methodology 79
8.4 Forecasting Methodology 79
8.4.1 Diagnosed Osteoporosis Patients 79
8.4.2 Percent Drug-Treated Patients 79
8.4.3 Drugs Included in Each Therapeutic Class 80
8.4.4 General Pricing Assumptions 80
8.4.5 Individual Drug Assumptions 80
8.4.6 Generic Erosion 84
8.5 Physicians and Specialists Included in this Study 85
8.5.1 About the Authors 86
8.5.2 Global Head of Healthcare 87
8.6 About GlobalData 88
8.7 Contact Us 88
8.8 Disclaimer 88

List of Tables

Table 1: Etiology of Primary Osteoporosis 12
Table 2: Etiology of Secondary Osteoporosis 14
Table 3: Symptoms of Osteoporosis 17
Table 4: Diagnostic Tests for Osteoporosis 18
Table 5: T-Score Ranges for Determination of BMD 19
Table 6: Treatment Guidelines for Osteoporosis 20
Table 7: Most Prescribed Drugs for Osteoporosis by Therapeutic Class in the Global Markets, 2012 21
Table 8: Leading Treatments for Osteoporosis, 2012 28
Table 9: Product Profile – Actonel 30
Table 10: Actonel SWOT Analysis, 2012 31
Table 11: Product Profile – Evista 33
Table 12: Evista SWOT Analysis, 2012 34
Table 13: Product Profile – Reclast 36
Table 14: Reclast SWOT Analysis, 2012 37
Table 15: Product Profile – Forteo 39
Table 16: Mean Percent Change from Baseline in BMD with Forteo vs. Placebo in Postmenopausal Women with Osteoporosis 40
Table 17: Forteo SWOT Analysis, 2012 41
Table 18: Product Profile – Prolia 42
Table 19: Prolia SWOT Analysis, 2012 44
Table 20: Product Profile – Protelos 45
Table 21: Protelos SWOT Analysis, 2012 46
Table 22: Product Profile – Miacalcin and Fortical Nasal Spray 49
Table 23: Adverse Events with Miacalcin Nasal Spray 49
Table 24: Miacalcin and Fortical Nasal Spray SWOT Analysis, 2012 50
Table 25: Product Profile – Viviant/Conbriza 52
Table 26: Viviant/Conbriza SWOT Analysis, 2012 53
Table 27: Product Profile – Recalbon/Bonoteo 54
Table 28: Recalbon/Bonoteo SWOT Analysis, 2012 55
Table 29: Overall Unmet Needs – Current Level of Attainment 59
Table 30: Clinical Unmet Needs – Gap Analysis, 2012 63
Table 31: China Sales Forecasts ($m) for Osteoporosis, 2012-2022 67
Table 32: Key Events Impacting Sales for Osteoporosis in the China, 2012–2022 68
Table 33: Osteoporosis Market – Drivers and Barriers in China, 2012–2022 69
Table 34: Number of High-Prescribing Physicians Surveyed 85